2009
DOI: 10.21859/isv.3.3.1
|View full text |Cite
|
Sign up to set email alerts
|

Development of an ELISA Test for Detection of Anti FMD Virus Type A87/IRN Antibody Using Irradiated Antigen

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 10 publications
0
3
0
Order By: Relevance
“…The dose of irradiation did not appear to affect the immunogenicity of the virus. Foot and mouth disease (FMD) is inactivated by irradiation within the range 40,000–44,000 Gy (Motamedi-Sedeh et al 2009 ). In guinea pigs, irradiation-attenuated FMD viruses induced neutralizing antibodies that persisted for up to 8 months, post-vaccination—a similar duration to that obtained using conventional FMD vaccine.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The dose of irradiation did not appear to affect the immunogenicity of the virus. Foot and mouth disease (FMD) is inactivated by irradiation within the range 40,000–44,000 Gy (Motamedi-Sedeh et al 2009 ). In guinea pigs, irradiation-attenuated FMD viruses induced neutralizing antibodies that persisted for up to 8 months, post-vaccination—a similar duration to that obtained using conventional FMD vaccine.…”
Section: Introductionmentioning
confidence: 99%
“…A gamma-irradiated inactivated cell culture derived African horse sickness viral antigen has been used in a blocking ELISA (B-ELISA) for detecting antibody to a subgroup-reactive epitope of African horse sickness virus (House et al 1996 ). Foot and mouth disease virus irradiated from 10,000 to 45,000 Gy appeared to have unaltered antigenicity in blocking ELISA tests (Motamedi-Sedeh et al 2009 ).…”
Section: Introductionmentioning
confidence: 99%
“…These experimental animals and natural hosts' immune responses led to the production of virus-neutralizing antibodies and viral challenge protection [1]. For diagnostic application, VP1 protein type O was expressed in E. coli, and the purified antibodies and protein were then tested against clinical samples from various serotypes using the ELISA method [19][20][21].…”
Section: Discussionmentioning
confidence: 99%